BACKGROUND: Lipoprotein (a) [Lp (a)] is a well-established risk factor for coronary artery disease (CAD). However, up till now, treatment of patients with higher Lp (a) levels is challenging. This current study aimed to investigate the therapeutic effects of short-, medium and long-term statin use on the Lp (a) reduction and its modifying factors. METHODS: The therapeutic duration was categorized into short-term (median, 39 days), medium term (median, 219 days) and long-term (median, 677 days). The lipid profiles before therapy served as baselines. Patients at short-, medium or long-term exactly matched with those at baseline. Every patient's lipid profiles during the follow-ups were compared to his own ones at baselines. RESULTS: The current study demonstrated that long-term statin therapy significantly decreased the Lp (a) levels in CAD patients while short-term or medium term statin therapy didn't. When grouped by statin use, only long-term simvastatin use significantly decreased the Lp (a) levels while long-term atorvastatin use insignificantly decreased the Lp (a) levels. Primary hypertension (PH), DM, low density lipoprotein cholesterol (LDL-C) and high density lipoprotein cholesterol (HDL-C) could modify the therapeutic effects of statin use on the Lp (a) levels in CAD patients. CONCLUSIONS: The long-term statin therapy could be efficacious in reducing the Lp (a) levels in CAD patients, which has been modified by some traditional risk factors. In the era of commercial unavailability of more reliable Lp (a) lowering drugs, our findings will bolster confidence in fighting higher Lp (a) abnormalities both for patients and for doctors.
BACKGROUND: Lipoprotein (a) [Lp (a)] is a well-established risk factor for coronary artery disease (CAD). However, up till now, treatment of patients with higher Lp (a) levels is challenging. This current study aimed to investigate the therapeutic effects of short-, medium and long-term statin use on the Lp (a) reduction and its modifying factors. METHODS: The therapeutic duration was categorized into short-term (median, 39 days), medium term (median, 219 days) and long-term (median, 677 days). The lipid profiles before therapy served as baselines. Patients at short-, medium or long-term exactly matched with those at baseline. Every patient's lipid profiles during the follow-ups were compared to his own ones at baselines. RESULTS: The current study demonstrated that long-term statin therapy significantly decreased the Lp (a) levels in CAD patients while short-term or medium term statin therapy didn't. When grouped by statin use, only long-term simvastatin use significantly decreased the Lp (a) levels while long-term atorvastatin use insignificantly decreased the Lp (a) levels. Primary hypertension (PH), DM, low density lipoprotein cholesterol (LDL-C) and high density lipoprotein cholesterol (HDL-C) could modify the therapeutic effects of statin use on the Lp (a) levels in CAD patients. CONCLUSIONS: The long-term statin therapy could be efficacious in reducing the Lp (a) levels in CAD patients, which has been modified by some traditional risk factors. In the era of commercial unavailability of more reliable Lp (a) lowering drugs, our findings will bolster confidence in fighting higher Lp (a) abnormalities both for patients and for doctors.
Authors: Fatima Akdim; Maartje E Visser; Diane L Tribble; Brenda F Baker; Erik S G Stroes; Rosie Yu; Joann D Flaim; John Su; Evan A Stein; John J P Kastelein Journal: Am J Cardiol Date: 2010-03-30 Impact factor: 2.778
Authors: Richard C Pasternak; Sidney C Smith; C Noel Bairey-Merz; Scott M Grundy; James I Cleeman; Claude Lenfant Journal: J Am Coll Cardiol Date: 2002-08-07 Impact factor: 24.094
Authors: Corina Serban; T Nicola; Rodica Mateescu; Lavinia Noveanu; Lelia Susan; Alina Pacurari; A Caraba; I Romoşan; A Cristescu Journal: Rev Med Chir Soc Med Nat Iasi Date: 2010 Jul-Sep
Authors: Sophie Gonbert; Sophie Malinsky; Andrei C Sposito; Hervé Laouenan; Chantal Doucet; M John Chapman; Joëlle Thillet Journal: Atherosclerosis Date: 2002-10 Impact factor: 5.162
Authors: Sotirios Tsimikas; Nicholas J Viney; Steven G Hughes; Walter Singleton; Mark J Graham; Brenda F Baker; Jennifer L Burkey; Qingqing Yang; Santica M Marcovina; Richard S Geary; Rosanne M Crooke; Joseph L Witztum Journal: Lancet Date: 2015-07-22 Impact factor: 79.321
Authors: Gérald Luc; Jean-Marie Bard; Dominique Arveiler; Jean Ferrieres; Alun Evans; Philippe Amouyel; Jean-Charles Fruchart; Pierre Ducimetiere Journal: Atherosclerosis Date: 2002-08 Impact factor: 5.162
Authors: Frederick F Samaha; James McKenney; Leanne T Bloedon; William J Sasiela; Daniel J Rader Journal: Nat Clin Pract Cardiovasc Med Date: 2008-05-27
Authors: Edward J Mills; Beth Rachlis; Ping Wu; Philip J Devereaux; Paul Arora; Dan Perri Journal: J Am Coll Cardiol Date: 2008-11-25 Impact factor: 24.094